Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,926,156
  • Shares Outstanding, K 171,386
  • Annual Sales, $ 654,700 K
  • Annual Income, $ -222,690 K
  • 60-Month Beta 1.98
  • Price/Sales 22.41
  • Price/Cash Flow N/A
  • Price/Book 10.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 9
  • High Estimate -0.15
  • Low Estimate -0.58
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.24 +5.94%
on 01/13/20
118.65 -6.93%
on 01/24/20
-2.99 (-2.64%)
since 12/27/19
3-Month
101.59 +8.70%
on 10/28/19
122.36 -9.75%
on 11/25/19
+7.81 (+7.61%)
since 10/25/19
52-Week
62.90 +75.56%
on 05/15/19
122.36 -9.75%
on 11/25/19
+37.69 (+51.81%)
since 01/25/19

Most Recent Stories

More News
Seattle Genetics Set to Possibly Pullback After Yesterday's Rally of 2.26%

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $108.18 to a high of $111.24. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high...

SGEN : 110.43 (-2.76%)
Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe

Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.

ABBV : 84.02 (+0.57%)
RHHBY : 40.9700 (-0.56%)
AMGN : 222.95 (-1.17%)
SGEN : 110.43 (-2.76%)
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following...

SGEN : 110.43 (-2.76%)
Seattle Genetics Achieves Milestone Following European Commission Approval of Roche's Polivy(R) (Polatuzumab Vedotin)

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy(R) (polatuzumab...

SGEN : 110.43 (-2.76%)
Seattle Genetics Up More Than 40% in the Past Year: Here's Why

Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.

MRK : 86.10 (+0.14%)
RHHBY : 40.9700 (-0.56%)
EPZM : 21.36 (-4.64%)
SGEN : 110.43 (-2.76%)
'Guided-Missile' Cancer Drugs are the Biotech Sector's First Major Story of the 2020s

USA News Group - With a new decade still less than a month underway, it appears the 2020s should see some major breakthroughs in the fight against cancer. A recent analysis from Reuters uncovered that...

ONCY : 3.14 (-3.98%)
ONC.TO : 4.12 (-3.29%)
RHHBY : 40.9700 (-0.56%)
SGEN : 110.43 (-2.76%)
AZN : 48.90 (-0.77%)
IMMU : 18.06 (-1.20%)
Seattle Genetics Set to Possibly Rebound After Yesterday's Selloff of 6.71%

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $104.50 to a high of $112.23. Yesterday, the shares fell 6.7%, which took the trading range below the 3-day low of...

SGEN : 110.43 (-2.76%)
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time. Both the presentation...

JPM : 132.03 (-0.84%)
SGEN : 110.43 (-2.76%)
Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline

Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.

PFE : 40.16 (+0.85%)
SGEN : 110.43 (-2.76%)
ALPMY : 17.1400 (-1.52%)
BOLD : 59.97 (-0.02%)
Seattle Genetics Submits NDA to FDA for Tucatinib Combo

Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.

RHHBY : 40.9700 (-0.56%)
AZN : 48.90 (-0.77%)
ALKS : 17.15 (-2.67%)
SGEN : 110.43 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 114.26
1st Resistance Point 112.35
Last Price 110.43
1st Support Level 108.69
2nd Support Level 106.95

See More

52-Week High 122.36
Last Price 110.43
Fibonacci 61.8% 99.65
Fibonacci 50% 92.63
Fibonacci 38.2% 85.61
52-Week Low 62.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar